JP2017537919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537919A5 JP2017537919A5 JP2017529321A JP2017529321A JP2017537919A5 JP 2017537919 A5 JP2017537919 A5 JP 2017537919A5 JP 2017529321 A JP2017529321 A JP 2017529321A JP 2017529321 A JP2017529321 A JP 2017529321A JP 2017537919 A5 JP2017537919 A5 JP 2017537919A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- composition
- subject
- antigen
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 257
- 239000000203 mixture Substances 0.000 claims description 79
- 210000004027 cell Anatomy 0.000 claims description 66
- 239000000427 antigen Substances 0.000 claims description 60
- 102000036639 antigens Human genes 0.000 claims description 60
- 108091007433 antigens Proteins 0.000 claims description 60
- 201000010099 disease Diseases 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 230000011664 signaling Effects 0.000 claims description 22
- 230000000139 costimulatory effect Effects 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 11
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 9
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 9
- 102000007079 Peptide Fragments Human genes 0.000 claims description 9
- 108010033276 Peptide Fragments Proteins 0.000 claims description 9
- 230000024932 T cell mediated immunity Effects 0.000 claims description 9
- 230000028996 humoral immune response Effects 0.000 claims description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000036210 malignancy Effects 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108700010039 chimeric receptor Proteins 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000026683 transduction Effects 0.000 claims description 3
- 238000010361 transduction Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 51
- 150000001413 amino acids Chemical class 0.000 description 12
- 108090000144 Human Proteins Proteins 0.000 description 8
- 102000003839 Human Proteins Human genes 0.000 description 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022069168A JP2022101625A (ja) | 2014-12-03 | 2022-04-20 | 養子細胞療法のための方法および組成物 |
| JP2024102175A JP2024120077A (ja) | 2014-12-03 | 2024-06-25 | 養子細胞療法のための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087224P | 2014-12-03 | 2014-12-03 | |
| US62/087,224 | 2014-12-03 | ||
| PCT/US2015/063839 WO2016090190A1 (en) | 2014-12-03 | 2015-12-03 | Methods and compositions for adoptive cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069168A Division JP2022101625A (ja) | 2014-12-03 | 2022-04-20 | 養子細胞療法のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537919A JP2017537919A (ja) | 2017-12-21 |
| JP2017537919A5 true JP2017537919A5 (https=) | 2019-01-17 |
| JP7068820B2 JP7068820B2 (ja) | 2022-05-17 |
Family
ID=55022703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529321A Active JP7068820B2 (ja) | 2014-12-03 | 2015-12-03 | 養子細胞療法のための方法および組成物 |
| JP2022069168A Pending JP2022101625A (ja) | 2014-12-03 | 2022-04-20 | 養子細胞療法のための方法および組成物 |
| JP2024102175A Pending JP2024120077A (ja) | 2014-12-03 | 2024-06-25 | 養子細胞療法のための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069168A Pending JP2022101625A (ja) | 2014-12-03 | 2022-04-20 | 養子細胞療法のための方法および組成物 |
| JP2024102175A Pending JP2024120077A (ja) | 2014-12-03 | 2024-06-25 | 養子細胞療法のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11266739B2 (https=) |
| EP (2) | EP3766895B1 (https=) |
| JP (3) | JP7068820B2 (https=) |
| KR (2) | KR20250067192A (https=) |
| CN (1) | CN107206025A (https=) |
| AU (3) | AU2015358400B2 (https=) |
| CA (1) | CA2969456A1 (https=) |
| ES (2) | ES2819553T3 (https=) |
| MX (2) | MX392416B (https=) |
| WO (1) | WO2016090190A1 (https=) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101605421B1 (ko) | 2014-03-05 | 2016-03-23 | 국립암센터 | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 |
| CA2946312A1 (en) | 2014-04-23 | 2015-10-29 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| MX392487B (es) | 2014-10-20 | 2025-03-21 | Juno Therapeutics Inc | Métodos y composiciones para dosificación en terapia celular adoptiva. |
| FI3240805T3 (fi) | 2014-12-15 | 2025-02-17 | Univ California | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| EP3365453A2 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
| PL3368571T3 (pl) | 2015-10-30 | 2023-05-02 | The Regents Of The University Of California | Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania |
| EP4212547A1 (en) * | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| US20180135011A1 (en) * | 2017-03-13 | 2018-05-17 | Berkeley Lights, Inc. | Selection and cloning of t lymphocytes in a microfluidic device |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP6994021B2 (ja) * | 2016-08-26 | 2022-01-14 | ジュノー セラピューティクス インコーポレイテッド | 細胞組成物中に存在する粒子を計数する方法 |
| EP3518943A4 (en) | 2016-09-28 | 2020-04-22 | Atossa Therapeutics, Inc. | METHOD FOR ADAPTIVE CELL THERAPY |
| DK3523326T3 (da) * | 2016-10-04 | 2020-08-03 | Prec Biosciences Inc | Samstimulerende domæner til anvendelse i genetisk modificerede celler |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| US20200095547A1 (en) * | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| KR20190098747A (ko) * | 2016-12-05 | 2019-08-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료법을 위한 조작된 세포의 제조방법 |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| WO2018154386A1 (en) * | 2017-02-21 | 2018-08-30 | Eutilex Co., Ltd. | Hla-dr car-t compositions and methods of making and using the same |
| MX2019010906A (es) | 2017-03-14 | 2020-02-12 | Juno Therapeutics Inc | Metodos para almacenamiento criogenico. |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN110573177A (zh) * | 2017-04-28 | 2019-12-13 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) |
| CA3065930A1 (en) | 2017-06-07 | 2018-12-13 | Intrexon Corporation | Expression of novel cell tags |
| MX2019014584A (es) | 2017-06-07 | 2020-02-07 | Seattle Genetics Inc | Celulas t con fucosilacion de superficie reducida y metodos para preparar y usar las mismas. |
| JP2020526194A (ja) * | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | 免疫療法薬と関連する毒性を評価するためのマウスモデル |
| KR20250016455A (ko) | 2017-08-09 | 2025-02-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법 |
| PT3703750T (pt) | 2017-11-01 | 2025-01-17 | Memorial Sloan Kettering Cancer Center | Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes |
| US12258580B2 (en) | 2017-11-01 | 2025-03-25 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| MX2020005907A (es) | 2017-12-08 | 2020-10-19 | Juno Therapeutics Inc | Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. |
| CN119193493A (zh) * | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN109988242A (zh) * | 2018-01-02 | 2019-07-09 | 武汉波睿达生物科技有限公司 | 联合嵌合抗原受体、表达载体、慢病毒及t细胞 |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| MA52114A (fr) | 2018-02-28 | 2021-01-06 | Juno Therapeutics Inc | Procédés de détection de particules présentes dans une composition cellulaire |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| KR102551319B1 (ko) | 2018-05-14 | 2023-07-05 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| US12516099B2 (en) | 2018-08-09 | 2026-01-06 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| AU2019317229A1 (en) | 2018-08-10 | 2021-02-18 | Eutilex Co.,Ltd | Chimeric Antigen Receptor that Binds HLA-DR, and CAR-T Cell |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| MA54078A (fr) | 2018-11-01 | 2021-09-15 | Juno Therapeutics Inc | Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| EP4032972A4 (en) * | 2019-09-18 | 2024-07-24 | Slbigen Inc. | GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH A GENE ENCODING A NEW CHIMERIC ANTIGEN RECEPTOR AND ITS USE |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| JP7439279B2 (ja) * | 2020-02-13 | 2024-02-27 | イミュノファーム テクノロジー カンパニー リミテッド | キメラ抗原受容体の最適化 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| IL297327B2 (en) | 2020-05-01 | 2026-01-01 | Gilead Sciences Inc | 4,2-dioxopyrimidine compounds CD73 inhibitors |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| WO2022032665A1 (zh) * | 2020-08-14 | 2022-02-17 | 上海星华生物医药科技有限公司 | 一种制备通用型免疫细胞的方法及其应用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4476267A4 (en) * | 2022-02-11 | 2026-01-07 | Fred Hutchinson Cancer Center | CHIMERIC ANTIGENIC RECEPTORS BINDING TO STEAP1 |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| WO2025212519A1 (en) | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (https=) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| AU4746590A (en) | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| ATE338124T1 (de) | 2000-11-07 | 2006-09-15 | Hope City | Cd19-spezifische umgezielte immunzellen |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7355012B2 (en) | 2001-09-26 | 2008-04-08 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| ES2660180T3 (es) | 2007-12-07 | 2018-03-21 | Miltenyi Biotec Gmbh | Sistemas y métodos para procesamiento de células |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| WO2009124109A1 (en) | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| AU2010263272C1 (en) * | 2009-06-24 | 2016-02-11 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| TR201904484T4 (tr) | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| JP5712516B2 (ja) * | 2010-07-14 | 2015-05-07 | 住友電気工業株式会社 | 半導体装置 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| US9366138B2 (en) * | 2011-07-28 | 2016-06-14 | Pratt & Whitney Canada Corp. | Rotary internal combustion engine with phasing gear |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| CN104080797A (zh) | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| EP2844743B1 (en) | 2012-05-03 | 2021-01-13 | Fred Hutchinson Cancer Research Center | Enhanced affinity t cell receptors and methods for making the same |
| JP2015524255A (ja) | 2012-07-13 | 2015-08-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法 |
| BR122020002986A8 (pt) | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| MX370148B (es) | 2012-10-02 | 2019-12-03 | Memorial Sloan Kettering Cancer Center | Composiciones y su uso para inmunoterapia. |
| RU2658485C2 (ru) | 2012-10-24 | 2018-06-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы м971 |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| IL311390A (en) | 2013-03-15 | 2024-05-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| US10611837B2 (en) | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| MX392487B (es) | 2014-10-20 | 2025-03-21 | Juno Therapeutics Inc | Métodos y composiciones para dosificación en terapia celular adoptiva. |
| CN104910279B (zh) | 2015-06-05 | 2019-02-22 | 重庆精准生物技术有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
| EP4212547A1 (en) | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| EP4212166A1 (en) | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Compositions and methods for reducing immune responses against cell therapies |
-
2015
- 2015-12-03 ES ES15816318T patent/ES2819553T3/es active Active
- 2015-12-03 EP EP20180622.1A patent/EP3766895B1/en active Active
- 2015-12-03 US US14/958,919 patent/US11266739B2/en active Active
- 2015-12-03 CA CA2969456A patent/CA2969456A1/en active Pending
- 2015-12-03 MX MX2017007138A patent/MX392416B/es unknown
- 2015-12-03 CN CN201580075303.2A patent/CN107206025A/zh active Pending
- 2015-12-03 JP JP2017529321A patent/JP7068820B2/ja active Active
- 2015-12-03 AU AU2015358400A patent/AU2015358400B2/en active Active
- 2015-12-03 WO PCT/US2015/063839 patent/WO2016090190A1/en not_active Ceased
- 2015-12-03 ES ES20180622T patent/ES2987087T3/es active Active
- 2015-12-03 KR KR1020257014535A patent/KR20250067192A/ko active Pending
- 2015-12-03 KR KR1020177018369A patent/KR102804498B1/ko active Active
- 2015-12-03 EP EP15816318.8A patent/EP3227323B1/en active Active
-
2017
- 2017-06-05 MX MX2022005955A patent/MX2022005955A/es unknown
-
2020
- 2020-12-04 AU AU2020281158A patent/AU2020281158B2/en active Active
-
2022
- 2022-01-28 US US17/588,149 patent/US20220280642A1/en active Pending
- 2022-04-20 JP JP2022069168A patent/JP2022101625A/ja active Pending
-
2023
- 2023-10-20 US US18/491,633 patent/US20240066122A1/en active Pending
-
2024
- 2024-04-07 AU AU2024202225A patent/AU2024202225A1/en active Pending
- 2024-06-25 JP JP2024102175A patent/JP2024120077A/ja active Pending
-
2025
- 2025-06-23 US US19/246,568 patent/US20250312446A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537919A5 (https=) | ||
| RU2623161C2 (ru) | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака | |
| US20200199254A1 (en) | Identification of vsig8 as the putative vista receptor (v-r) and use thereof to produce vista/vsig8 agonists and antagonists | |
| US20160272707A1 (en) | Vstm5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases | |
| AU2013239662B2 (en) | Anti-SEMA4D antibodies and epitopes | |
| JP2019527537A5 (https=) | ||
| AU2012277376B2 (en) | Polypeptides and uses thereof for treatment of autoimmune disorders and infection | |
| WO2015037000A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| JP2018531914A5 (https=) | ||
| JP2018512145A5 (https=) | ||
| RU2017142716A (ru) | Конструкции, направленные на комплексы пептида hpv16-e7/мнс, и виды их использования | |
| JP2019513394A5 (https=) | ||
| CN112955221A (zh) | 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途 | |
| JP2023532278A5 (https=) | ||
| US12269887B2 (en) | Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using | |
| RU2803148C2 (ru) | Противоопухолевое средство и способ его оценки | |
| WO2025242827A1 (en) | Bispecific antibody against pd-l1 and cd137 in combination therapy | |
| HK40067100A (zh) | Cd22特异性人源化抗体及利用其的嵌合抗原受体 | |
| EA051364B1 (ru) | Улучшенные антигенсвязывающие рецепторы | |
| RU2021134337A (ru) | Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения | |
| RU2022128701A (ru) | Нацеливание на клетки, опосредуемое химерным антигенным рецептором | |
| HK1224686A1 (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| HK1224686A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| HK1191033A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| HK1191033B (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |